Real‐world experience of the feasibility and tolerability of the 2/1 dosing schedule with sunitinib in the treatment of patients with advanced renal cell carcinoma in Australia
Megan Crumbaker; Alexander Guminski; Howard Gurney; Dhanusha Sabanathan; Shirley Wong; Nick Pavlakis
Author Information: Royal North Shore Hospital
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.